熱門資訊> 正文

Adagio Therapeutics GAAP每股收益为-1.81美元

2024-03-28 19:23

Adagio Therapeutics press release (NASDAQ:IVVD): FY GAAP EPS of -$1.81.
Cash and cash equivalents were $200.6 million as of December 31, 2023.
Based on current operating plans and excluding anticipated cash collections from PEMGARDA sales, Invivyd expects its existing total cash and cash equivalents will enable the company to fund its operating expenses and capital expenditure requirements into the fourth quarter of 2024.

More on Adagio Therapeutics

Morgan Stanley ups Invivyd to overweight, cites FDA EUA decision
Invivyd stock soars on FDA EUA for COVID-19 prophylaxis drug
Seeking Alpha’s Quant Rating on Adagio Therapeutics
Historical earnings data for Adagio Therapeutics
Financial information for Adagio Therapeutics

推薦文章

風險及免責提示：以上內容僅代表作者的個人立場和觀點，不代表華盛的任何立場，華盛亦無法證實上述內容的真實性、準確性和原創性。投資者在做出任何投資決定前，應結合自身情況，考慮投資產品的風險。必要時，請諮詢專業投資顧問的意見。華盛不提供任何投資建議，對此亦不做任何承諾和保證。